Evidence map›Paper›PMID 26193084›Full record

ArticleBrain pathology (Zurich, Switzerland)2016

Precortical Phase of Alzheimer's Disease (AD)-Related Tau Cytoskeletal Pathology.

Katharina Stratmann, Helmut Heinsen, Horst-Werner Korf, Domenico Del Turco, Estifanos Ghebremedhin, Kay Seidel, Mohamed Bouzrou, Lea T Grinberg, Jürgen Bohl, Stephen B Wharton and 2 more

Abstract read
In one paragraph

Article in Brain pathology (Zurich, Switzerland), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 113 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
113citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

113 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. An updated overview of recent and ongoing deep brain stimulation (DBS) trials in patients with dementia: a systematic review.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023
    Pooled it
  2. Salivary lactoferrin as biomarker for Alzheimer's disease: Brain-immunity interactions.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2020
    Pooled it
  3. Trial
  4. Article
  5. Review
  6. Article
  7. Measuring in-vivo tau pathology in the basal forebrain with PET imaging.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2026
    Article
  8. Article
  9. Article
  10. Neuromodulatory subcortical systems in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  11. Article
  12. Stress, stress systems, and Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  13. Article
  14. Article
  15. Thalamic nuclei insights into Alzheimer's disease.bioRxiv : the preprint server for biology · 2026
    Article
  16. Article
  17. Night-to-night rapid eye movement sleep variability: A relevant marker of early amyloid-β deposition.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Observational
  18. Wake-promoting neuromodulators in Alzheimer's disease: Implications for sleep and brain clearance.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  19. Implication of the thalamus in sleep alterations observed in Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review
  20. Sex differences in neuromodulatory subcortical systems and their implications for Alzheimer's disease.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Review

53 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Katharina StratmannDr. Senckenbergisches Chronomedizinisches Institut, Goethe University, Frankfurt/Main, Germany.
Helmut HeinsenMorphological Brain Research Unit, Psychiatric Clinic, Julius Maximilians University Würzburg, Würzburg, Germany.
Horst-Werner KorfDr. Senckenbergisches Chronomedizinisches Institut, Goethe University, Frankfurt/Main, Germany.
Domenico Del TurcoInstitute of Clinical Neuroanatomy, Neuroscience Center, Goethe University, Frankfurt/Main, Germany.
Estifanos GhebremedhinInstitute of Clinical Neuroanatomy, Neuroscience Center, Goethe University, Frankfurt/Main, Germany.
Kay SeidelDr. Senckenbergisches Chronomedizinisches Institut, Goethe University, Frankfurt/Main, Germany.
Mohamed BouzrouDr. Senckenbergisches Chronomedizinisches Institut, Goethe University, Frankfurt/Main, Germany.
Lea T GrinbergDepartment of Neurology, Memory and Aging Center, University of California at San Francisco, San Francisco, CA.
Jürgen BohlNeuropathology Division, University Clinic of Mainz, Mainz, Germany.
Stephen B WhartonSheffield Institute for Translational Neuroscience, University of Sheffield, Sheffield, UK.
Wilfred den DunnenDepartment of Pathology and Medical Biology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands.
Udo RübDr. Senckenbergisches Chronomedizinisches Institut, Goethe University, Frankfurt/Main, Germany.

Funding

PrPSc SPECIFIC INTERACTION WITH NOVEL PrP-Fc FUSION PROTEINSP50AG023501 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MILLER, BRUCE L · 2004 to 2018
$27.1M
Brainstem as an early site in AD and FTLD: closing the etiopathogenic gapR01AG040311 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRINBERG, LEA TENENHOLZ · 2011 to 2015
$2.0M
Medical Research Council G0300126Medical Research Council G0900582Medical Research Council G9901400Medical Research Council MR/J004308/1NIA NIH HHS P50 AG023501NIA NIH HHS R01 AG040311
6 · The paper itself

Abstract

Alzheimer's disease (AD) represents the most frequent progressive neuropsychiatric disorder worldwide leading to dementia. We systematically investigated the presence and extent of the AD-related cytoskeletal pathology in serial thick tissue sections through all subcortical brain nuclei that send efferent projections to the transentorhinal and entorhinal regions in three individuals with Braak and Braak AD stage 0 cortical cytoskeletal pathology and fourteen individuals with Braak and Braak AD stage I cortical cytoskeletal pathology by means of immunostainings with the anti-tau antibody AT8. These investigations revealed consistent AT8 immunoreactive tau cytoskeletal pathology in a subset of these subcortical nuclei in the Braak and Braak AD stage 0 individuals and in all of these subcortical nuclei in the Braak and Braak AD stage I individuals. The widespread affection of the subcortical nuclei in Braak and Braak AD stage I shows that the extent of the early subcortical tau cytoskeletal pathology has been considerably underestimated previously. In addition, our novel findings support the concept that subcortical nuclei become already affected during an early 'pre-cortical' evolutional phase before the first AD-related cytoskeletal changes occur in the mediobasal temporal lobe (i.e. allocortical transentorhinal and entorhinal regions). The very early involved subcortical brain regions may represent the origin of the AD-related tau cytoskeletal pathology, from where the neuronal cytoskeletal pathology takes an ascending course toward the secondarily affected allocortex and spreads transneuronally along anatomical pathways in predictable sequences.

Indexed as

tau ProteinsAgedAlzheimer DiseaseBrainCytoskeletonDisease ProgressionFemaleHumansMaleMiddle Agedtau ProteinsallocortexAlzheimer's diseasecytoskeletal pathologyentorhinal regionprion-like diseasessubcortical nucleitau protein

Identifiers

PMID26193084
PMCPMC4720581

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.